|
DGAP-News: M1 Kliniken AG
/ Key word(s): Annual Results
Supervisory Board of M1 Kliniken AG adopts (consolidated) financial statements 2021 of M1 Kliniken AG. No deviations from the preliminary figures for financial year 2021 published at the end of March - Supervisory Board adopts the 2021 annual financial statements of M1 Kliniken AG, which have been audited with unqualified audit opinions - Turnover almost doubles to almost 315 million euros. Group operating result (EBIT) almost tripled to €12.1 million (€4.4 million in 2020) - The Supervisory Board and the Executive Board propose to the Annual General Meeting that the balance sheet profit be carried forward in full to new account. Investments in sustainable growth planned. Berlin, 4 May 2022 - At its meeting yesterday, the Supervisory Board of M1 Kliniken AG adopted the annual financial statements of M1 Kliniken AG (separate financial statements according to HGB and consolidated financial statements according to IFRS), which were issued with unqualified audit opinions. The preliminary figures already communicated at the end of March 2022 were confirmed in full. In the future, the M1 Group will continue to focus clearly on growth and the development of new market segments. For example, Haemato AG is increasingly concentrating on the product business and the implementation of a clinical study for the European approval of its own Botox product in cooperation with Huons Bioharma from South Korea. M1 will push the expansion of the practice network in Germany and internationally with the goal of developing the number of operating locations towards 100 in the next three years. Against this background and in order to secure the financing of growth, the Supervisory Board and the Executive Board decided in its meeting today to propose to the Annual General Meeting that the balance sheet profit be carried forward in full to new account. The Annual Report 2021 of M1 Kliniken AG will be published on 19 May 2022.
Contact: M1 Kliniken AG Dr. Walter von Horstig, Management Board Grünauer Straße 5 12557 Berlin T: +49 (0)30 347 47 44 14 M: ir@m1-kliniken.de
04.05.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
| Language: | English |
| Company: | M1 Kliniken AG |
| Grünauer Straße 5 | |
| 12557 Berlin | |
| Germany | |
| Phone: | +49 (0)30 347 47 44 14 |
| Fax: | +49 (0)30 347 47 44 17 |
| E-mail: | ir@m1-kliniken.de |
| Internet: | https://www.m1-kliniken.de |
| ISIN: | DE000A0STSQ8 |
| WKN: | A0STSQ |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1342809 |
| End of News | DGAP News Service |
|
|
1342809 04.05.2022
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
